Pfizer says COVID vaccine is 90% effective in 5- to 11-year olds

Date:

Share post:

School leaders’ efforts to keep educating kids in person got a big boost with Pfizer’s vaccine showing 90% effectiveness in preventing COVID in 5- to 11-year-olds.

Two smaller doses of the Pfizer-BioNTech were 90.7% effective at preventing symptomatic cases of COVID-19 in children 5- to 11-years old, the companies announced Friday.

The vaccine shows “a favorable safety and tolerability profile” and “robust immune responses against all variants of concern including Delta,” in the younger kids, the company said in data submitted to the U.S. Food and Drug Administration.

This age group could begin getting shots before Thanksgiving—the FDA will meet next and the CDC on Nov. 2-3 to consider approving the vaccines for children 5-11. In anticipation of approval, the Biden Administration this week released its plan for rapidly distributing and administering the vaccines.

Pediatricians, who the administration intends to supply with ample vaccine and smaller needles, will be one the main sources of vaccinations for children this fall. Schools will also play a key role in hosting vaccination clinics, the administration says.

The CDC has recorded 1.8 million cases of COVID among children 5-11, including more than 8,600 hospitalizations and 138 deaths.

“Preventing COVID-19 will not only provide direct health benefits to children 5 to <12 years of age, but indirect educational and social development benefits can be anticipated based on alleviating the disruption to in-person education caused by COVID-19 outbreaks in school settings,” Pfizer said. “Facilitating the return to school may also have associated economic and social benefits for children’s families.”

Pfizer says it is still studying the risk of the vaccine causing myocarditis—an inflammation of the heart—in younger children. The company noted that data from Israel show the condition is rare but most common in males aged 16-19, and the risk drops for adolescents 12 to 15 years of age.

The company believes the risk for 5-11-year-olds should be even lower because they will get a smaller dose of the vaccine.

Matt Zalaznick
Matt Zalaznick
Matt Zalaznick is the managing editor of District Administration, covering K-12 public school leadership, teaching and learning, student achievement, education technology, and federal education policy. A journalist since 1996, Zalaznick has reported on politics, law enforcement, and breaking news for newspapers and websites across the U.S. Virgin Islands, the San Francisco Bay Area, Colorado, and the New York City suburbs. He holds a B.A. in English from Tufts University.

The Always-On Insight and Networking Platform for Superintendents and Their Teams

AI-driven insights peer-to-peer collaboration and more build exclusively for K-12 Superintendents and thier leaders
Built for the uniqueness of the superintendent role and their supporting team.Most platforms treat all K–12 leaders the same. DA+ recognizes that superintendents face a unique level of pressure, complexity, visibility, and responsibility—and gives them a space designed specifically for the demands of the top job.
A community where you don’t have to explain the context.Skip the backstory. DA+ understands the job, the politics, the stakes, and the pace.
Your decisions shape communities.Find the tools and peer insight to make them with confidence here.
Leadership tailored to the realities of running a district.From board relations to budgets, crisis response to community trust—DA+ focuses on the challenges only superintendents navigate each day.
Built for superintendents.Powered by superintendents. Trusted by superintendents. If you run a district, you belong here.

Related Articles